Pharvaris (NASDAQ:PHVS) Stock Price Up 8%

Pharvaris (NASDAQ:PHVS) shares rose 8% on Monday . The stock traded as high as $20.69 and last traded at $20.69. Approximately 23,719 shares traded hands during trading, a decline of 77% from the average daily volume of 103,124 shares. The stock had previously closed at $19.16.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Morgan Stanley reaffirmed an “overweight” rating and set a $34.00 target price on shares of Pharvaris in a report on Monday. JMP Securities upped their target price on shares of Pharvaris from $49.00 to $50.00 and gave the company a “market outperform” rating in a report on Thursday, April 11th. Finally, Wedbush reaffirmed an “outperform” rating and set a $35.00 target price on shares of Pharvaris in a report on Thursday, April 11th.

Pharvaris Stock Performance

The stock’s 50-day moving average is $23.73 and its two-hundred day moving average is $23.34.

Hedge Funds Weigh In On Pharvaris

Several institutional investors have recently bought and sold shares of PHVS. Hudson Bay Capital Management LP bought a new position in Pharvaris during the third quarter valued at $812,000. Walleye Capital LLC raised its position in Pharvaris by 15.2% in the 3rd quarter. Walleye Capital LLC now owns 81,017 shares of the company’s stock worth $1,691,000 after purchasing an additional 10,691 shares during the period. Blackstone Inc. bought a new stake in Pharvaris in the fourth quarter worth about $2,805,000. Vivo Capital LLC purchased a new position in shares of Pharvaris during the fourth quarter valued at approximately $7,994,000. Finally, Commodore Capital LP bought a new position in shares of Pharvaris during the fourth quarter valued at approximately $22,440,000.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).